Sfoglia per Rivista TARGETED ONCOLOGY
An analysis of the treatment effect of panitumumab on overall survival from a phase 3, randomized, controlled, multicenter trial (20020408) in patients with chemotherapy refractory metastatic colorectal cancer
2013 M. Poulin-Costello, L. Azoulay, E. Van Cutsem, M. Peeters, S. Siena, M. Wolf
Angiogenesis Genotyping and Clinical Outcomes in Patients with Advanced Hepatocellular Carcinoma Receiving Sorafenib: The ALICE-2 Study
2020 L. Faloppi, M. Puzzoni, A. Casadei Gardini, N. Silvestris, G. Masi, G. Marisi, C. Vivaldi, C.D. Gadaleta, P. Ziranu, M. Bianconi, C. Loretelli, L. Demurtas, E. Lai, R. Giampieri, E. Galizia, P. Ulivi, N. Battelli, A. Falcone, S. Cascinu, M. Scartozzi
Clinical retrospective analysis of erlotinib in the treatment of elderly patients with advanced non-small cell lung cancer
2011 M. Platania, F. Agustoni, B. Formisano, M. Vitali, M. Ducceschi, F. Pietrantonio, N. Zilembo, F. Gelsomino, S. Pusceddu, R. Buzzoni
Controversial evaluation of EGFR protein and gene status in predicting response to anti-EGFR monoclonal antibodies in metastatic colorectal cancer: A case report and review of the literature
2008 M. Moroni, S. Veronese, A. Sartore-Bianchi, S. Artale, S. Siena
Dose-Dense Temozolomide in Patients with MGMT-Silenced Chemorefractory Colorectal Cancer
2016 F. Pietrantonio, F. de Braud, M. Milione, C. Maggi, R. Iacovelli, K.F. Dotti, F. Perrone, E. Tamborini, M. Caporale, R. Berenato, G. Leone, A. Pellegrinelli, I. Bossi, F. Festinese, S. Federici, M. Di Bartolomeo
Erratum: Integrated molecular dissection of the epidermal growth factor receptor (EGFR) oncogenic pathway to predict response to EGFR-targeted monoclonal antibodies in metastatic colorectal cancer
2012 A. Sartore Bianchi, K. Bencardino, F. Di Nicolantonio, F. Pozzi, C. Funaioli, V. Gambi, S. Arena, M. Martini, S. Lamba, A. Cassingena, R. Schiavo, A. Bardelli, S. Siena
Integrated molecular dissection of the epidermal growth factor receptor (EFGR) oncogenic pathway to predict response to EGFR-targeted monoclonal antibodies in metastatic colorectal cancer
2010 A. Sartore Bianchi, K. Bencardino, F. Di Nicolantonio, F. Pozzi, C. Funaioli, V. Gambi, S. Arena, M. Martini, S. Lamba, A. Cassingena, R. Schiavo, A. Bardelli, S. Siena
Lack of KRAS, NRAS, BRAF and TP53 mutations improves outcome of elderly metastatic colorectal cancer patients treated with cetuximab, oxaliplatin and UFT
2014 M. Di Bartolomeo, F. Pietrantonio, F. Perrone, K.F. Dotti, A. Lampis, C. Bertan, E. Beretta, L. Rimassa, C. Carbone, P. Biondani, R. Passalacqua, S. Pilotti, E. Bajetta
Liquid Biopsy for Prognosis and Treatment in Metastatic Colorectal Cancer: Circulating Tumor Cells vs Circulating Tumor DNA
2021 G. Patelli, C. Vaghi, F. Tosi, G. Mauri, A. Amatu, D. Massihnia, S. Ghezzi, E. Bonazzina, K. Bencardino, G. Cerea, S. Siena, A. Sartore Bianchi
Low Baseline Serum Sodium Concentration Is Associated with Poor Clinical Outcomes in Metastatic Non-Small Cell Lung Cancer Patients Treated with Immunotherapy
2018 G. Fucà, G. Galli, M. Poggi, G. Lo Russo, C. Proto, M. Imbimbo, M. Vitali, M. Ganzinelli, C. Lanti, G. Molino, F. Stangoni, N. Zilembo, F. de Braud, M. Garassino, D. Signorelli
The Pan-Immune-Inflammation Value in Patients with Metastatic Melanoma Receiving First-Line Therapy
2021 G. Fuca, T. Beninato, M. Bini, L. Mazzeo, L. Di Guardo, C. Cimminiello, G. Randon, G. Apollonio, I. Bisogno, M. Del Vecchio, C. Lauria Pantano, M. Di Nicola, F. de Braud, M. Del Vecchio
Phase I Study of Rucaparib in Combination with Bevacizumab in Ovarian Cancer Patients: Maximum Tolerated Dose and Pharmacokinetic Profile
2021 D. Lorusso, G. Maltese, I. Sabatucci, S. Cresta, C. Matteo, T. Ceruti, M. D'Incalci, M. Zucchetti, F. Raspagliesi, C. Sonetto, V. Sinno, D. Ronzulli, S. Giolitto, F. de Braud
Pooled Analysis of Clinical Outcome of Patients with Chemorefractory Metastatic Colorectal Cancer Treated within Phase I/II Clinical Studies Based on Individual Biomarkers of Susceptibility : a Single-Institution Experience
2017 A. Sartore-Bianchi, A. Amatu, E. Bonazzina, S. Stabile, L. Giannetta, G. Cerea, I. Schiavetto, K. Bencardino, C. Funaioli, R. Ricotta, T. Cipani, M. Schirru, V. Gambi, L. Palmeri, G. Carlo-Stella, F. Rusconi, S. Di Bella, G. Burrafato, A. Cassingena, E. Valtorta, C. Lauricella, F. Pazzi, A. Gambaro, S. Ghezzi, G. Marrapese, E. Tarenzi, S. Veronese, M. Truini, A. Vanzulli, S. Siena
QTc prolongation induced by targeted biotherapies used in clinical practice and under investigation : a comprehensive review
2015 M. Locatelli, C. Criscitiello, A. Esposito, I. Minchella, A. Goldhirsch, C. Cipolla, G. Curigliano
Ramucirumab as Second-Line Therapy in Metastatic Gastric Cancer : Real-World Data from the RAMoss Study
2018 M. Di Bartolomeo, M. Niger, G. Tirino, A. Petrillo, R. Berenato, M.M. Laterza, F. Pietrantonio, F. Morano, M. Antista, S. Lonardi, L. Fornaro, S. Tamberi, E. Giommoni, A. Zaniboni, L. Rimassa, G. Tomasello, T. Sava, M. Spada, T. Latiano, A. Bittoni, A. Bertolini, I. Proserpio, K.B. Bencardino, F. Graziano, G. Beretta, S. Galdy, J. Ventriglia, S. Scagnoli, A. Spallanzani, R. Longarini, F. De Vita
Retreatment with Vismodegib after Progression in Advanced Basal Cell Carcinoma: First-Time Report of a Single-Institution Experience
2018 S. Alfieri, C. Bergamini, R. Granata, L. Locati, L. Licitra, P. Bossi
The Role of Mesothelin as a Diagnostic and Therapeutic Target in Pancreatic Ductal Adenocarcinoma : a Comprehensive Review
2018 F. Nichetti, A. Marra, F. Corti, A. Guidi, A. Raimondi, N. Prinzi, F. de Braud, S. Pusceddu
Treatment of Advanced Merkel Cell Carcinoma : Current Therapeutic Options and Novel Immunotherapy Approaches
2018 D. Femia, N. Prinzi, A. Anichini, R. Mortarini, F. Nichetti, F. Corti, M. Torchio, G. Peverelli, F. Pagani, A. Maurichi, I. Mattavelli, M. Milione, N. Bedini, A. Corti, M. Di Bartolomeo, F. de Braud, S. Pusceddu
Legenda icone
- file ad accesso aperto
- file disponibili sulla rete interna
- file disponibili agli utenti autorizzati
- file disponibili solo agli amministratori
- file sotto embargo
- nessun file disponibile